In 1995, the FDA approved alendronate, brand name Fosamax for postmenopausal osteoporosis treatment, a condition that affects over eight million women as well as causes 1.5 million fractures every year in the United States. It is a bone-we…
Quote saved.
Login to quote this blog
Failed to save quote. Please try again later.
You cannot quote because this article is private.